Skip to main content
Top
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

High efficiency of alphaviral gene transfer in combination with 5-fluorouracil in a mouse mammary tumor model

Authors: Anna Zajakina, Jelena Vasilevska, Dmitry Zhulenkovs, Dace Skrastina, Artjoms Spaks, Aiva Plotniece, Tatjana Kozlovska

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

The combination of virotherapy and chemotherapy may enable efficient tumor regression that would be unachievable using either therapy alone. In this study, we investigated the efficiency of transgene delivery and the cytotoxic effects of alphaviral vector in combination with 5-fluorouracil (5-FU) in a mouse mammary tumor model (4 T1).

Methods

Replication-deficient Semliki Forest virus (SFV) vectors carrying genes encoding fluorescent proteins were used to infect 4 T1 cell cultures treated with different doses of 5-FU. The efficiency of infection was monitored via fluorescence microscopy and quantified by fluorometry. The cytotoxicity of the combined treatment with 5-FU and alphaviral vector was measured using an MTT-based cell viability assay. In vivo experiments were performed in a subcutaneous 4 T1 mouse mammary tumor model with different 5-FU doses and an SFV vector encoding firefly luciferase.

Results

Infection of 4 T1 cells with SFV prior to 5-FU treatment did not produce a synergistic anti-proliferative effect. An alternative treatment strategy, in which 5-FU was used prior to virus infection, strongly inhibited SFV expression. Nevertheless, in vivo experiments showed a significant enhancement in SFV-driven transgene (luciferase) expression upon intratumoral and intraperitoneal vector administration in 4 T1 tumor-bearing mice pretreated with 5-FU: here, we observed a positive correlation between 5-FU dose and the level of luciferase expression.

Conclusions

Although 5-FU inhibited SFV-mediated transgene expression in 4 T1 cells in vitro, application of the drug in a mouse model revealed a significant enhancement of intratumoral transgene synthesis compared with 5-FU untreated mice. These results may have implications for efficient transgene delivery and the development of potent cancer treatment strategies using alphaviral vectors and 5-FU.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Naik JD, Twelves CJ, Selby PJ, Vile RG, Chester JD: Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?. Clin Cancer Res. 2011, 17: 4214-4224.CrossRefPubMedPubMedCentral Naik JD, Twelves CJ, Selby PJ, Vile RG, Chester JD: Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?. Clin Cancer Res. 2011, 17: 4214-4224.CrossRefPubMedPubMedCentral
3.
go back to reference Eralp Y, Wang X, Wang JP, Maughan MF, Polo JM, Lachman LB: Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res. 2004, 6: R275-R283.CrossRefPubMedPubMedCentral Eralp Y, Wang X, Wang JP, Maughan MF, Polo JM, Lachman LB: Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res. 2004, 6: R275-R283.CrossRefPubMedPubMedCentral
4.
go back to reference Cabrele C, Vogel M, Piso P, Rentsch M, Schroder J, Jauch KW, Schlitt HJ, Beham A: 5-Fluorouracil-related enhancement of adenoviral infection is Coxsackievirus-adenovirus receptor independent and associated with morphological changes in lipid membranes. World J Gastroenterol. 2006, 12: 5168-5174.PubMedPubMedCentral Cabrele C, Vogel M, Piso P, Rentsch M, Schroder J, Jauch KW, Schlitt HJ, Beham A: 5-Fluorouracil-related enhancement of adenoviral infection is Coxsackievirus-adenovirus receptor independent and associated with morphological changes in lipid membranes. World J Gastroenterol. 2006, 12: 5168-5174.PubMedPubMedCentral
5.
go back to reference Glasgow GM, McGee MM, Tarbatt CJ, Mooney DA, Sheahan BJ, Atkins GJ: The Semliki Forest virus vector induces p53-independent apoptosis. J Gen Virol. 1998, 79 (Pt 10): 2405-2410.CrossRefPubMed Glasgow GM, McGee MM, Tarbatt CJ, Mooney DA, Sheahan BJ, Atkins GJ: The Semliki Forest virus vector induces p53-independent apoptosis. J Gen Virol. 1998, 79 (Pt 10): 2405-2410.CrossRefPubMed
6.
go back to reference Venticinque L, Meruelo D: Sindbis viral vector induced apoptosis requires translational inhibition and signaling through Mcl-1 and Bak. Mol Cancer. 2010, 9: 37-CrossRefPubMedPubMedCentral Venticinque L, Meruelo D: Sindbis viral vector induced apoptosis requires translational inhibition and signaling through Mcl-1 and Bak. Mol Cancer. 2010, 9: 37-CrossRefPubMedPubMedCentral
8.
go back to reference Riezebos-Brilman A, De MA, Bungener L, Huckriede A, Wilschut J, Daemen T: Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy. J Clin Virol. 2006, 35: 233-243.CrossRefPubMed Riezebos-Brilman A, De MA, Bungener L, Huckriede A, Wilschut J, Daemen T: Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy. J Clin Virol. 2006, 35: 233-243.CrossRefPubMed
9.
go back to reference Liljestrom P, Garoff H: A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (N Y). 1991, 9: 1356-1361.CrossRef Liljestrom P, Garoff H: A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (N Y). 1991, 9: 1356-1361.CrossRef
10.
go back to reference Bredenbeek PJ, Frolov I, Rice CM, Schlesinger S: Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs. J Virol. 1993, 67: 6439-6446.PubMedPubMedCentral Bredenbeek PJ, Frolov I, Rice CM, Schlesinger S: Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs. J Virol. 1993, 67: 6439-6446.PubMedPubMedCentral
11.
go back to reference Urban C, Rheme C, Maerz S, Berg B, Pick R, Nitschke R, Borner C: Apoptosis induced by Semliki Forest virus is RNA replication dependent and mediated via Bak. Cell Death Differ. 2008, 15: 1396-1407.CrossRefPubMed Urban C, Rheme C, Maerz S, Berg B, Pick R, Nitschke R, Borner C: Apoptosis induced by Semliki Forest virus is RNA replication dependent and mediated via Bak. Cell Death Differ. 2008, 15: 1396-1407.CrossRefPubMed
12.
go back to reference Maatta AM, Makinen K, Ketola A, Liimatainen T, Yongabi FN, Vaha-Koskela M, Pirinen R, Rautsi O, Pellinen R, Hinkkanen A, Wahlfors J: Replication competent Semliki Forest virus prolongs survival in experimental lung cancer. Int J Cancer. 2008, 123: 1704-1711.CrossRefPubMed Maatta AM, Makinen K, Ketola A, Liimatainen T, Yongabi FN, Vaha-Koskela M, Pirinen R, Rautsi O, Pellinen R, Hinkkanen A, Wahlfors J: Replication competent Semliki Forest virus prolongs survival in experimental lung cancer. Int J Cancer. 2008, 123: 1704-1711.CrossRefPubMed
13.
go back to reference Ketola A, Hinkkanen A, Yongabi F, Furu P, Maatta AM, Liimatainen T, Pirinen R, Björn M, Hakkarainen T, Mäkinen K, Wahlfors J, Pellinen R: Oncolytic Semliki forest virus vector as a novel candidate against unresectable osteosarcoma. Cancer Res. 2008, 68: 8342-8350.CrossRefPubMed Ketola A, Hinkkanen A, Yongabi F, Furu P, Maatta AM, Liimatainen T, Pirinen R, Björn M, Hakkarainen T, Mäkinen K, Wahlfors J, Pellinen R: Oncolytic Semliki forest virus vector as a novel candidate against unresectable osteosarcoma. Cancer Res. 2008, 68: 8342-8350.CrossRefPubMed
14.
go back to reference Maatta AM, Liimatainen T, Wahlfors T, Wirth T, Vaha-Koskela M, Jansson L, Valonen P, Häkkinen K, Rautsi O, Pellinen R, Mäkinen K, Hakumäki J, Hinkkanen A, Wahlfors J: Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models. Int J Cancer. 2007, 121: 863-870.CrossRefPubMed Maatta AM, Liimatainen T, Wahlfors T, Wirth T, Vaha-Koskela M, Jansson L, Valonen P, Häkkinen K, Rautsi O, Pellinen R, Mäkinen K, Hakumäki J, Hinkkanen A, Wahlfors J: Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models. Int J Cancer. 2007, 121: 863-870.CrossRefPubMed
15.
go back to reference Zhang YQ, Tsai YC, Monie A, Wu TC, Hung CF: Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy. Mol Ther. 2010, 18: 692-699.CrossRefPubMedPubMedCentral Zhang YQ, Tsai YC, Monie A, Wu TC, Hung CF: Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy. Mol Ther. 2010, 18: 692-699.CrossRefPubMedPubMedCentral
16.
go back to reference Asselin-Paturel C, Lassau N, Guinebretiere JM, Zhang J, Gay F, Bex F, Hallez S, Leclere J, Peronneau P, Mami-Chouaib F, Chouaib S: Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography. Gene Ther. 1999, 6: 606-615.CrossRefPubMed Asselin-Paturel C, Lassau N, Guinebretiere JM, Zhang J, Gay F, Bex F, Hallez S, Leclere J, Peronneau P, Mami-Chouaib F, Chouaib S: Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography. Gene Ther. 1999, 6: 606-615.CrossRefPubMed
17.
go back to reference Chikkanna-Gowda CP, Sheahan BJ, Fleeton MN, Atkins GJ: Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12. Gene Ther. 2005, 12: 1253-1263.CrossRefPubMed Chikkanna-Gowda CP, Sheahan BJ, Fleeton MN, Atkins GJ: Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12. Gene Ther. 2005, 12: 1253-1263.CrossRefPubMed
18.
go back to reference Rodriguez-Madoz JR, Prieto J, Smerdou C: Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas. Mol Ther. 2005, 12: 153-163.CrossRefPubMed Rodriguez-Madoz JR, Prieto J, Smerdou C: Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas. Mol Ther. 2005, 12: 153-163.CrossRefPubMed
19.
go back to reference Lyons JA, Sheahan BJ, Galbraith SE, Mehra R, Atkins GJ, Fleeton MN: Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice. Gene Ther. 2007, 14: 503-513.CrossRefPubMed Lyons JA, Sheahan BJ, Galbraith SE, Mehra R, Atkins GJ, Fleeton MN: Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice. Gene Ther. 2007, 14: 503-513.CrossRefPubMed
20.
go back to reference Morse MA, Hobeika AC, Osada T, Berglund P, Hubby B, Negri S, Niedzwiecki D, Devi GR, Burnett BK, Clay TM, Smith J, Lyerly HK: An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J Clin Invest. 2010, 120: 3234-3241.CrossRefPubMedPubMedCentral Morse MA, Hobeika AC, Osada T, Berglund P, Hubby B, Negri S, Niedzwiecki D, Devi GR, Burnett BK, Clay TM, Smith J, Lyerly HK: An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J Clin Invest. 2010, 120: 3234-3241.CrossRefPubMedPubMedCentral
21.
go back to reference Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L: Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology. 2013, 2: e24612-CrossRefPubMedPubMedCentral Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L: Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology. 2013, 2: e24612-CrossRefPubMedPubMedCentral
22.
go back to reference Eisenberg DP, Adusumilli PS, Hendershott KJ, Yu Z, Mullerad M, Chan MK, Chou TC, Fong Y: 5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer. J Gastrointest Surg. 2005, 9: 1068-1077.CrossRefPubMedPubMedCentral Eisenberg DP, Adusumilli PS, Hendershott KJ, Yu Z, Mullerad M, Chan MK, Chou TC, Fong Y: 5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer. J Gastrointest Surg. 2005, 9: 1068-1077.CrossRefPubMedPubMedCentral
23.
go back to reference Meng S, Zhou Z, Chen F, Kong X, Liu H, Jiang K, Liu W, Hu M, Zhang X, Ding C, Wu Y: Newcastle disease virus induces apoptosis in cisplatin-resistant human lung adenocarcinoma A549 cells in vitro and in vivo. Cancer Lett. 2012, 317: 56-64.CrossRefPubMed Meng S, Zhou Z, Chen F, Kong X, Liu H, Jiang K, Liu W, Hu M, Zhang X, Ding C, Wu Y: Newcastle disease virus induces apoptosis in cisplatin-resistant human lung adenocarcinoma A549 cells in vitro and in vivo. Cancer Lett. 2012, 317: 56-64.CrossRefPubMed
24.
go back to reference Zhuang X, Zhang W, Chen Y, Han X, Li J, Zhang Y, Zhang Y, Zhang S, Liu B: Doxorubicin-enriched, ALDH(br) mouse breast cancer stem cells are treatable to oncolytic herpes simplex virus type 1. BMC Cancer. 2012, 12: 549-CrossRefPubMedPubMedCentral Zhuang X, Zhang W, Chen Y, Han X, Li J, Zhang Y, Zhang Y, Zhang S, Liu B: Doxorubicin-enriched, ALDH(br) mouse breast cancer stem cells are treatable to oncolytic herpes simplex virus type 1. BMC Cancer. 2012, 12: 549-CrossRefPubMedPubMedCentral
25.
go back to reference Heinemann L, Simpson GR, Boxall A, Kottke T, Relph KL, Vile R, Melcher A, Prestwich R, Harrington KJ, Morgan R, Pandha HS: Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer. 2011, 11: 221-CrossRefPubMedPubMedCentral Heinemann L, Simpson GR, Boxall A, Kottke T, Relph KL, Vile R, Melcher A, Prestwich R, Harrington KJ, Morgan R, Pandha HS: Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer. 2011, 11: 221-CrossRefPubMedPubMedCentral
26.
go back to reference Halloran CM, Ghaneh P, Shore S, Greenhalf W, Zumstein L, Wilson D, Neoptolemos JP, Costello E: 5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells. J Gene Med. 2004, 6: 514-525.CrossRefPubMed Halloran CM, Ghaneh P, Shore S, Greenhalf W, Zumstein L, Wilson D, Neoptolemos JP, Costello E: 5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells. J Gene Med. 2004, 6: 514-525.CrossRefPubMed
27.
go back to reference Hallden G: Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics. J BUON. 2009, 14 (Suppl 1): S61-S67.PubMed Hallden G: Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics. J BUON. 2009, 14 (Suppl 1): S61-S67.PubMed
28.
go back to reference Qiu S, Ruan H, Pei Z, Hu B, Lan P, Wang J, Zhang Z, Gu J, Sun L, Qian C, Liu X, Qi Y: Combination of Targeting Gene-ViroTherapy with 5-FU enhances antitumor efficacy in malignant colorectal carcinoma. J Interferon Cytokine Res. 2004, 24: 219-230.CrossRefPubMed Qiu S, Ruan H, Pei Z, Hu B, Lan P, Wang J, Zhang Z, Gu J, Sun L, Qian C, Liu X, Qi Y: Combination of Targeting Gene-ViroTherapy with 5-FU enhances antitumor efficacy in malignant colorectal carcinoma. J Interferon Cytokine Res. 2004, 24: 219-230.CrossRefPubMed
29.
go back to reference Uchida H, Shinoura N, Kitayama J, Watanabe T, Nagawa H, Hamada H: 5-Fluorouracil efficiently enhanced apoptosis induced by adenovirus-mediated transfer of caspase-8 in DLD-1 colon cancer cells. J Gene Med. 2003, 5: 287-299.CrossRefPubMed Uchida H, Shinoura N, Kitayama J, Watanabe T, Nagawa H, Hamada H: 5-Fluorouracil efficiently enhanced apoptosis induced by adenovirus-mediated transfer of caspase-8 in DLD-1 colon cancer cells. J Gene Med. 2003, 5: 287-299.CrossRefPubMed
30.
go back to reference Kadota K, Huang CL, Liu D, Yokomise H, Haba R, Wada H: Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors. Int J Oncol. 2011, 38: 355-363.PubMed Kadota K, Huang CL, Liu D, Yokomise H, Haba R, Wada H: Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors. Int J Oncol. 2011, 38: 355-363.PubMed
31.
go back to reference Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, Newbold K, Gore ME, Larkin J, Syrigos KN, Coffey M, Thompson B, Mettinger K, Vile RG, Pandha HS, Hall GD, Melcher AA, Chester J, Harrington KJ: Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res. 2012, 18: 2080-2089.CrossRefPubMed Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, Newbold K, Gore ME, Larkin J, Syrigos KN, Coffey M, Thompson B, Mettinger K, Vile RG, Pandha HS, Hall GD, Melcher AA, Chester J, Harrington KJ: Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res. 2012, 18: 2080-2089.CrossRefPubMed
32.
go back to reference Hecht JR, Farrell JJ, Senzer N, Nemunaitis J, Rosemurgy A, Chung T, Hanna N, Chang KJ, Javle M, Posner M, Waxman I, Reid A, Erickson R, Canto M, Chak A, Blatner G, Kovacevic M, Thornton M: EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. Gastrointest Endosc. 2012, 75: 332-338.CrossRefPubMedPubMedCentral Hecht JR, Farrell JJ, Senzer N, Nemunaitis J, Rosemurgy A, Chung T, Hanna N, Chang KJ, Javle M, Posner M, Waxman I, Reid A, Erickson R, Canto M, Chak A, Blatner G, Kovacevic M, Thornton M: EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. Gastrointest Endosc. 2012, 75: 332-338.CrossRefPubMedPubMedCentral
33.
go back to reference Granot T, Meruelo D: The role of natural killer cells in combinatorial anti-cancer therapy using Sindbis viral vectors and irinotecan. Cancer Gene Ther. 2012, 19: 588-591.CrossRefPubMed Granot T, Meruelo D: The role of natural killer cells in combinatorial anti-cancer therapy using Sindbis viral vectors and irinotecan. Cancer Gene Ther. 2012, 19: 588-591.CrossRefPubMed
34.
go back to reference Matz MV, Fradkov AF, Labas YA, Savitsky AP, Zaraisky AG, Markelov ML, Lukyanov SA: Fluorescent proteins from nonbioluminescent Anthozoa species. Nat Biotechnol. 1999, 17: 969-973.CrossRefPubMed Matz MV, Fradkov AF, Labas YA, Savitsky AP, Zaraisky AG, Markelov ML, Lukyanov SA: Fluorescent proteins from nonbioluminescent Anthozoa species. Nat Biotechnol. 1999, 17: 969-973.CrossRefPubMed
35.
go back to reference Vasilevska J, Skrastina D, Spunde K, Garoff H, Kozlovska T, Zajakina A: Semliki Forest virus biodistribution in tumor-free and 4 T1 mammary tumor-bearing mice: a comparison of transgene delivery by recombinant virus particles and naked RNA replicon. Cancer Gene Ther. 2012, 19: 579-587.CrossRefPubMed Vasilevska J, Skrastina D, Spunde K, Garoff H, Kozlovska T, Zajakina A: Semliki Forest virus biodistribution in tumor-free and 4 T1 mammary tumor-bearing mice: a comparison of transgene delivery by recombinant virus particles and naked RNA replicon. Cancer Gene Ther. 2012, 19: 579-587.CrossRefPubMed
36.
go back to reference Akhrymuk I, Kulemzin SV, Frolova EI: Evasion of the innate immune response: the Old World alphavirus nsP2 protein induces rapid degradation of Rpb1, a catalytic subunit of RNA polymerase II. J Virol. 2012, 86: 7180-7191.CrossRefPubMedPubMedCentral Akhrymuk I, Kulemzin SV, Frolova EI: Evasion of the innate immune response: the Old World alphavirus nsP2 protein induces rapid degradation of Rpb1, a catalytic subunit of RNA polymerase II. J Virol. 2012, 86: 7180-7191.CrossRefPubMedPubMedCentral
37.
go back to reference Burke CW, Gardner CL, Steffan JJ, Ryman KD, Klimstra WB: Characteristics of alpha/beta interferon induction after infection of murine fibroblasts with wild-type and mutant alphaviruses. Virology. 2009, 395: 121-132.CrossRefPubMedPubMedCentral Burke CW, Gardner CL, Steffan JJ, Ryman KD, Klimstra WB: Characteristics of alpha/beta interferon induction after infection of murine fibroblasts with wild-type and mutant alphaviruses. Virology. 2009, 395: 121-132.CrossRefPubMedPubMedCentral
38.
go back to reference Egami T, Ohuchida K, Miyoshi K, Mizumoto K, Onimaru M, Toma H, Sato N, Matsumoto K, Tanaka M: Chemotherapeutic agents potentiate adenoviral gene therapy for pancreatic cancer. Cancer Sci. 2009, 100: 722-729.CrossRefPubMed Egami T, Ohuchida K, Miyoshi K, Mizumoto K, Onimaru M, Toma H, Sato N, Matsumoto K, Tanaka M: Chemotherapeutic agents potentiate adenoviral gene therapy for pancreatic cancer. Cancer Sci. 2009, 100: 722-729.CrossRefPubMed
39.
go back to reference Quetglas JI, Ruiz-Guillen M, Aranda A, Casales E, Bezunartea J, Smerdou C: Alphavirus vectors for cancer therapy. Virus Res. 2010, 153: 179-196.CrossRefPubMed Quetglas JI, Ruiz-Guillen M, Aranda A, Casales E, Bezunartea J, Smerdou C: Alphavirus vectors for cancer therapy. Virus Res. 2010, 153: 179-196.CrossRefPubMed
40.
41.
go back to reference Sun S, Wang LP, Zhang J, Yang XY, Zhang QL, Jia Z, Hu XC, Wang BY: Phase II study of oxaliplatin plus leucovorin and 5-fluorouracil in heavily pretreated metastatic breast cancer patients. Med Oncol. 2012, 29: 418-424.CrossRefPubMed Sun S, Wang LP, Zhang J, Yang XY, Zhang QL, Jia Z, Hu XC, Wang BY: Phase II study of oxaliplatin plus leucovorin and 5-fluorouracil in heavily pretreated metastatic breast cancer patients. Med Oncol. 2012, 29: 418-424.CrossRefPubMed
42.
go back to reference Kantelhardt EJ, Vetter M, Schmidt M, Veyret C, Augustin D, Hanf V, Meisner C, Paepke D, Schmitt M, Sweep F, von Minckwitz G, Martin PM, Jaenicke F, Thomssen C, Harbeck N: Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6xFEC versus 3xFEC/3xDocetaxel. BMC Cancer. 2011, 11: 140-CrossRefPubMedPubMedCentral Kantelhardt EJ, Vetter M, Schmidt M, Veyret C, Augustin D, Hanf V, Meisner C, Paepke D, Schmitt M, Sweep F, von Minckwitz G, Martin PM, Jaenicke F, Thomssen C, Harbeck N: Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6xFEC versus 3xFEC/3xDocetaxel. BMC Cancer. 2011, 11: 140-CrossRefPubMedPubMedCentral
43.
go back to reference Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003, 3: 330-338.CrossRefPubMed Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003, 3: 330-338.CrossRefPubMed
44.
go back to reference Garcia MA, Carrasco E, Aguilera M, Alvarez P, Rivas C, Campos JM, Prados JC, Calleja MA, Esteban M, Marchal JA, Aránega A: The chemotherapeutic drug 5-fluorouracil promotes PKR-mediated apoptosis in a p53-independent manner in colon and breast cancer cells. PLoS One. 2011, 6: e23887-CrossRefPubMedPubMedCentral Garcia MA, Carrasco E, Aguilera M, Alvarez P, Rivas C, Campos JM, Prados JC, Calleja MA, Esteban M, Marchal JA, Aránega A: The chemotherapeutic drug 5-fluorouracil promotes PKR-mediated apoptosis in a p53-independent manner in colon and breast cancer cells. PLoS One. 2011, 6: e23887-CrossRefPubMedPubMedCentral
45.
go back to reference Gorchakov R, Frolova E, Williams BR, Rice CM, Frolov I: PKR-dependent and -independent mechanisms are involved in translational shutoff during Sindbis virus infection. J Virol. 2004, 78: 8455-8467.CrossRefPubMedPubMedCentral Gorchakov R, Frolova E, Williams BR, Rice CM, Frolov I: PKR-dependent and -independent mechanisms are involved in translational shutoff during Sindbis virus infection. J Virol. 2004, 78: 8455-8467.CrossRefPubMedPubMedCentral
46.
go back to reference Yoon CH, Lee ES, Lim DS, Bae YS: PKR, a p53 target gene, plays a crucial role in the tumor-suppressor function of p53. Proc Natl Acad Sci U S A. 2009, 106: 7852-7857.CrossRefPubMedPubMedCentral Yoon CH, Lee ES, Lim DS, Bae YS: PKR, a p53 target gene, plays a crucial role in the tumor-suppressor function of p53. Proc Natl Acad Sci U S A. 2009, 106: 7852-7857.CrossRefPubMedPubMedCentral
47.
go back to reference Peidis P, Papadakis AI, Muaddi H, Richard S, Koromilas AE: Doxorubicin bypasses the cytoprotective effects of eIF2alpha phosphorylation and promotes PKR-mediated cell death. Cell Death Differ. 2011, 18: 145-154.CrossRefPubMed Peidis P, Papadakis AI, Muaddi H, Richard S, Koromilas AE: Doxorubicin bypasses the cytoprotective effects of eIF2alpha phosphorylation and promotes PKR-mediated cell death. Cell Death Differ. 2011, 18: 145-154.CrossRefPubMed
48.
go back to reference Zhao Q, Zhang W, Ning Z, Zhuang X, Lu H, Liang J, Li J, Zhang Y, Dong Y, Zhang Y, Zhang S, Liu S, Liu B: A novel oncolytic herpes simplex virus type 2 has potent anti-tumor activity. PLoS One. 2014, 9 (3): e93103-CrossRefPubMedPubMedCentral Zhao Q, Zhang W, Ning Z, Zhuang X, Lu H, Liang J, Li J, Zhang Y, Dong Y, Zhang Y, Zhang S, Liu S, Liu B: A novel oncolytic herpes simplex virus type 2 has potent anti-tumor activity. PLoS One. 2014, 9 (3): e93103-CrossRefPubMedPubMedCentral
49.
go back to reference Cheema TA, Kanai R, Kim GW, Wakimoto H, Passer B, Rabkin SD, Martuza RL: Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts. Clin Cancer Res. 2011, 17: 7383-7393.CrossRefPubMedPubMedCentral Cheema TA, Kanai R, Kim GW, Wakimoto H, Passer B, Rabkin SD, Martuza RL: Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts. Clin Cancer Res. 2011, 17: 7383-7393.CrossRefPubMedPubMedCentral
50.
go back to reference Kim DY, Firth AE, Atasheva S, Frolova EI, Frolov I: Conservation of a packaging signal and the viral genome RNA packaging mechanism in alphavirus evolution. J Virol. 2011, 85: 8022-8036.CrossRefPubMedPubMedCentral Kim DY, Firth AE, Atasheva S, Frolova EI, Frolov I: Conservation of a packaging signal and the viral genome RNA packaging mechanism in alphavirus evolution. J Virol. 2011, 85: 8022-8036.CrossRefPubMedPubMedCentral
51.
go back to reference Carreras CW, Santi DV: The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem. 1995, 64: 721-762.CrossRefPubMed Carreras CW, Santi DV: The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem. 1995, 64: 721-762.CrossRefPubMed
52.
go back to reference Bhattacharyya M, Francis J, Eddouadi A, Lemoine NR, Hallden G: An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine. Cancer Gene Ther. 2011, 18: 734-743.CrossRefPubMed Bhattacharyya M, Francis J, Eddouadi A, Lemoine NR, Hallden G: An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine. Cancer Gene Ther. 2011, 18: 734-743.CrossRefPubMed
53.
go back to reference Tu SP, Cui JT, Liston P, Huajiang X, Xu R, Lin MC, Zhu YB, Zou B, Ng SS, Jiang SH, Xia HH, Wong WM, Chan AO, Yuen MF, Lam SK, Kung HF, Wong BC: Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant. Gastroenterology. 2005, 128: 361-375.CrossRefPubMed Tu SP, Cui JT, Liston P, Huajiang X, Xu R, Lin MC, Zhu YB, Zou B, Ng SS, Jiang SH, Xia HH, Wong WM, Chan AO, Yuen MF, Lam SK, Kung HF, Wong BC: Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant. Gastroenterology. 2005, 128: 361-375.CrossRefPubMed
54.
go back to reference Leveille S, Samuel S, Goulet ML, Hiscott J: Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy. Cancer Gene Ther. 2011, 18: 435-443.CrossRefPubMed Leveille S, Samuel S, Goulet ML, Hiscott J: Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy. Cancer Gene Ther. 2011, 18: 435-443.CrossRefPubMed
55.
go back to reference Diasio RB, Harris BE: Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989, 16: 215-237.CrossRefPubMed Diasio RB, Harris BE: Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989, 16: 215-237.CrossRefPubMed
56.
go back to reference Greish K: Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target. 2007, 15: 457-464.CrossRefPubMed Greish K: Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target. 2007, 15: 457-464.CrossRefPubMed
57.
go back to reference Maeda H, Fang J, Inutsuka T, Kitamoto Y: Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol. 2003, 3: 319-328.CrossRefPubMed Maeda H, Fang J, Inutsuka T, Kitamoto Y: Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol. 2003, 3: 319-328.CrossRefPubMed
58.
go back to reference Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A: Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst. 2006, 98: 335-344.CrossRefPubMed Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A: Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst. 2006, 98: 335-344.CrossRefPubMed
59.
go back to reference Tseng JC, Granot T, DiGiacomo V, Levin B, Meruelo D: Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor. Cancer Gene Ther. 2010, 17: 244-255.CrossRefPubMed Tseng JC, Granot T, DiGiacomo V, Levin B, Meruelo D: Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor. Cancer Gene Ther. 2010, 17: 244-255.CrossRefPubMed
60.
go back to reference Huang PY, Guo JH, Hwang LH: Oncolytic Sindbis virus targets tumors defective in the interferon response and induces significant bystander antitumor immunity in vivo. Mol Ther. 2012, 20: 298-305.CrossRefPubMed Huang PY, Guo JH, Hwang LH: Oncolytic Sindbis virus targets tumors defective in the interferon response and induces significant bystander antitumor immunity in vivo. Mol Ther. 2012, 20: 298-305.CrossRefPubMed
61.
go back to reference Zhang Y, Burke CW, Ryman KD, Klimstra WB: Identification and characterization of interferon-induced proteins that inhibit alphavirus replication. J Virol. 2007, 81: 11246-11255.CrossRefPubMedPubMedCentral Zhang Y, Burke CW, Ryman KD, Klimstra WB: Identification and characterization of interferon-induced proteins that inhibit alphavirus replication. J Virol. 2007, 81: 11246-11255.CrossRefPubMedPubMedCentral
Metadata
Title
High efficiency of alphaviral gene transfer in combination with 5-fluorouracil in a mouse mammary tumor model
Authors
Anna Zajakina
Jelena Vasilevska
Dmitry Zhulenkovs
Dace Skrastina
Artjoms Spaks
Aiva Plotniece
Tatjana Kozlovska
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-460

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine